Investigation of the role of MMP3 -1171insA polymorphism in cutaneous malignant melanoma – A preliminary study

Biotechnology and Biotechnological Equipment

Volumn 28, Issue 5, 2014, Pages 904-910

  Vlaykova, Tatyana ^a   Kurzawski, Mateusz ^b   Tacheva, Tanya ^a   Dimov, Dimo ^a   Gulubova, Maya ^a   Yovchev, Yovcho ^a   Chakarov, Stoyan ^c   Drozdzik, Marek ^b  

^a TRAKIA UNIVERSITY   (Bulgaria)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

Genetic predisposition; MMP3; Skin malignant melanoma; Survival

Indexed keywords

DISEASES; ENZYME INHIBITION; GENE EXPRESSION; GENES; ONCOLOGY;

CUTANEOUS MALIGNANT MELANOMATA; GENETIC PREDISPOSITION; HARDY-WEINBERG EQUILIBRIUM; MALIGNANT MELANOMA; MATRIX METALLOPROTEINASES; MMP3; STATISTICALLY SIGNIFICANT DIFFERENCE; SURVIVAL;

DERMATOLOGY;

EID: 84912532631     PISSN: 13102818     EISSN: None     Source Type: Journal    
DOI: 10.1080/13102818.2014.947694     Document Type: Article

References (30)

1. Kaipainen A, Vlaykova T, Hatva E, Bohling T, Jekunen A, Pyrhonen S, Alitalo K. Enhanced expression of the tie receptor tyrosine kinase messenger RNA in the vascular endothelium of metastatic melanomas. Cancer Res. 1994;54:6571-6577.
2. Vlaykova T, Talve L, Hahka-Kemppinen M, Hernberg M, Muhonen T, Collan Y, Pyrhonen S. Immunohistochemically detectable Bcl-2 expression in metastatic melanoma: association with survival and treatment response. Oncology. 2002;62:259-268.
3. John A, Tuszynski G. The role of matrix metalloproteinases in tumour angiogenesis and tumour metastasis. Pathol Oncol Res. 2001;7:14-23.
4. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer. 2002;99:157-166.
5. O-Charoenrat P, Khantapura P. The role of genetic polymorphisms in the promoters of the matrix metalloproteinase- 2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol. 2006;42:257-267.
6. Anastasov A, Vihinen P, Nikkola J, Pyrhonen S, Vlaykova T. Matrix metalloproteinses in development and progression of skin malignant melanoma. Sci Technol Med. 2011;1:234-241.
7. Kerkela E, Saarialho-Kere U. Matrix metalloproteinases in tumour progression: focus on basal and squamous cell skin cancer. Exp Dermatol. 2003;12:109-125.
8. Nikkola J. Integrins and matrix metalloproteinases as prognostic factors in metastatic melanoma [PhD Thesis]. Turku: Turku University; 2004. 128 p.
9. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562-573.
10. Vlaykova T, Dimov D, Kurzawski M, Wajda A, Lapczuk J, Anastasov A, Drozdzik M. Frequencies of the common promoter polymorphisms in MMP1 and MMP3 genes in a Bulgarian population. Sci Technol Med. 2011;1:55-60.
11. Zielinnska A, Latocha M, Jurzak M, Kussmierz D. Expression of matrix metalloproteinases and theirs tissue inhibitors in fibroblast cultures and Colo-829 and SH-4 melanoma cultures after photodynamic therapy. In: Davids L, editor. Recent advances in the biology, therapy and management of melanoma. Rijeka: InTech; 2013. p. 1-21.
12. Vihinen P, Ala-Aho R, Kahari VM. Diagnostic and prognostic role of matrix metalloproteases in cancer. Expert Opin Med Diagn. 2008;2:1025-1039.
13. Vihinen P, Ala-aho R, Kahari VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets. 2005;5:203-220.
14. Clark IM, Swingler TE, Sampieri CL, Edwards DR. The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol. 2008;40:1362-1378.
15. Zhao Y, Chen S, Gou WF, Niu ZF, Zhao S, Xiao LJ, Takano Y, Zheng HC. The role of EMMPRIN expression in ovarian epithelial carcinomas. Cell Cycle. 2013;12:2899-2913.
16. Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez- Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2010;1803:3-19.
17. Walker RA, Woolley DE. Immunolocalisation studies of matrix metalloproteinases-1, -2 and -3 in human melanoma. Virchows Arch. 1999;435:574-579.
18. Bodey B, Bodey B Jr., Siegel SE, Kaiser HE. Matrix metalloproteinase expression in malignant melanomas: tumourextracellular matrix interactions in invasion and metastasis. In Vivo. 2001;15:57-64.
19. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase- 1 and stromelysin-1 correlate with shorter diseasefree survival in human metastatic melanoma. Int J Cancer. 2002;97:432-438.
20. Cotignola J, Roy P, Patel A, Ishill N, Shah S, Houghton A, Coit D, Halpern A, Busam K, Berwick M, Orlow I. Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression. J Negat Results Biomed. 2007;6:9.
21. Li X, Qu L, Zhong Y, Zhao Y, Chen H, Daru L. Association between promoters polymorphisms of matrix metalloproteinases and risk of digestive cancers: a meta-analysis. J Cancer Res Clin Oncol. 2013;139:1433-1447.
22. Hu C, Wang J, Xu Y, Li X, Chen H, Bunjhoo H, Xiong W, Xu Y, Zhao J. Current evidence on the relationship between five polymorphisms in the matrix metalloproteinases (MMP) gene and lung cancer risk: a meta-analysis. Gene. 2013;517:65-71.
23. Okamoto K, Ishida C, Ikebuchi Y, Mandai M, Mimura K, Murawaki Y, Yuasa I. The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCVrelated hepatocellular carcinoma. Intern Med. 2010;49:887-895.
24. Zhang C, Li C, Zhu M, Zhang Q, Xie Z, Niu G, Song X, Jin L, Li G, Zheng H. Meta-analysis of MMP2, MMP3, and MMP9 promoter polymorphisms and head and neck cancer risk. PLoS One. 2013;8:e62023.
25. Gonzalez-Arriaga P, Pascual T, Garcia-Alvarez A, Fernandez- Somoano A, Lopez-Cima MF, Tardon A. Genetic polymorphisms in MMP 2, 9 and 3 genes modify lung cancer risk and survival. BMC Cancer. 2012;12:1471-2407.
26. Ghilardi G, Biondi ML, Caputo M, Leviti S, DeMonti M, Guagnellini E, Scorza R. A single nucleotide polymorphism in the matrix metalloproteinase-3 promoter enhances breast cancer susceptibility. Clin Cancer Res. 2002;8:3820-3823.
27. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996;271: 13055-13060.
28. Frohlich E. Proteases in coetaneous malignant melanoma: relevance as biomarker and therapeutic target. Cell Mol Life Sci. 2010;67:3947-3960.
29. Tas F, Duranyildiz D, Oguz H, Disci R, Kurul S, Yasasever V, Topuz E. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 in patients with malignant melanoma. Med Oncol. 2005;22:39-44.
30. Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma. Med Oncol. 2008; 25:431-436.